(Q51385582)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

main subject

systemic inflammation

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

Robert Krysiak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

30 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Clinical Pharmacology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1459-1467

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

PPAR ligands: are they potential agents for cardiovascular disorders?

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Update on the use of fibrates: focus on bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Pathobiology of atherosclerosis--a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Cytokines in atherosclerosis: pathogenic and regulatory pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Inflammatory biomarkers in stable atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Inflammatory mechanisms in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Macrophages: promising targets for the treatment of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010382914

21 January 2018

Identifiers

DOI

10.1177/0091270010382914

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21119093%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference